Thyroid cancer radiotheragnostics: the case for activity adjusted 131I therapy
Authors:
- 4 August 2018
- journal article
- review article
- Published by Springer Nature in Clinical and Translational Imaging
- Vol. 6 (5) , 335-346
Abstract
Radiotheragnostics represents the systematic integration of diagnostic imaging and therapeutics using radionuclides targeting specific characteristics of tumor biology. Radioiodine (131I) is the classic radiotheragnostic agent used for the diagnosis and treatment of differentiated thyroid cancer based on sodium-iodine symporter expression in normal and neoplastic thyroid tissue. Application of radiotheragnostics principles in thyroid cancer involves using pre-ablation diagnostic scans (Dx Scans) for detection of iodine-avid regional and distant metastatic disease and patient-individualized targeted 131I therapy with goal of maximizing the benefits of the first therapeutic 131I administration. Clinically available nuclear medicine imaging technology has significantly evolved over the past 10 years with the introduction of hybrid SPECT/CT and PET/CT systems, as well as advances in iterative image reconstruction with modeling of image degrading physical factors. This progress makes possible the acquisition of accurate diagnostic radioiodine scintigraphy capable of identifying regional and distant metastatic disease, which can be used for 131I treatment planning and delivery of activity adjusted 131I therapy for achieving intended treatment goals (e.g., remnant ablation, adjuvant 131I treatment and targeted 131-I treatment). The overarching aim of thyroid cancer radiotheragnostics is to optimize the balance between 131I therapeutic efficacy and potential side-effects on non-target tissues.Keywords
Funding Information
- National Institute of Biomedical Imaging and Bioengineering (2-R01-EB-001994)
This publication has 84 references indexed in Scilit:
- MIRD Pamphlet No. 23: Quantitative SPECT for Patient-Specific 3-Dimensional Dosimetry in Internal Radionuclide TherapyJournal of Nuclear Medicine, 2012
- Ablation with Low-Dose Radioiodine and Thyrotropin Alfa in Thyroid CancerNew England Journal of Medicine, 2012
- Strategies of Radioiodine Ablation in Patients with Low-Risk Thyroid CancerNew England Journal of Medicine, 2012
- Radioiodine Scintigraphy with SPECT/CT: An Important Diagnostic Tool for Thyroid Cancer Staging and Risk StratificationJournal of Nuclear Medicine, 2012
- Treatment and follow-up of low-risk patients with thyroid cancerNature Reviews Endocrinology, 2011
- Three-dimensional radiobiological dosimetry (3D-RD) with 124I PET for 131I therapy of thyroid cancerEuropean Journal of Nuclear Medicine and Molecular Imaging, 2011
- The Benefits and Risks of I-131 Therapy in Patients with Well-Differentiated Thyroid CancerThyroid®, 2009
- Incidence of radiation thyroiditis and thyroid remnant ablation success rates following 1110 MBq (30 mCi) and 3700 MBq (100 mCi) post‐surgical 131I ablation therapy for differentiated thyroid carcinomaClinical Endocrinology, 2008
- Low vs. High Radioiodine Activity to Ablate the Thyroid after Thyroidectomy for Cancer: A Randomized StudyPLOS ONE, 2008
- Relation between Effective Radiation Dose and Outcome of Radioiodine Therapy for Thyroid CancerNew England Journal of Medicine, 1983